Lori Vincent
Psychiatric/Mental Health · Columbus, OHNPI 1104273101
Payments from drug & device makers
Across 282 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$741
- Teva Pharmaceuticals USA, Inc.$723
- E.r. Squibb & Sons, L.L.C.$644
- plus $1K from 7 others
What the payments were for
- Food & beverage$7,26697%
- Education$2403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $1,510 |
| Alkermes, Inc. | 55 | $1,246 |
| Axsome Therapeutics, Inc. | 26 | $1,166 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $741 |
| Teva Pharmaceuticals USA, Inc. | 13 | $723 |
| E.r. Squibb & Sons, L.L.C. | 26 | $644 |
| Otsuka America Pharmaceutical, Inc. | 11 | $507 |
| Johnson & Johnson | 9 | $427 |
| Indivior Inc. | 13 | $230 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Neurocrine Biosciences, Inc. | 6 | $106 |
| Relievant Medsystems, Inc. | 2 | $67 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,734
- VRAYLAR$843
- Auvelity$591
- CAPLYTA$483
- INVEGA SUSTENNA$269
- COBENFY$261
- ABILIFY MAINTENA$243
- ABILIFY ASIMTUFII$243
- Austedo XR$237
- AUSTEDO$121
- QUVIVIQ$121
- UZEDY$118
How this compares
$7,506 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 98 | $306,950 |
| IngrezzaValbenazine Tosylate | 18 | $146,238 |
| Abilify MaintenaAripiprazole | 36 | $104,831 |
| VraylarCariprazine Hcl | 70 | $99,067 |
| Risperdal ConstaRisperidone Microspheres | 88 | $81,710 |
| AristadaAripiprazole Lauroxil | 24 | $81,061 |
| AuvelityDextromethorphan Hbr/Bupropion | 35 | $38,410 |
| Lurasidone Hcl | 54 | $18,339 |
| RexultiBrexpiprazole | 12 | $16,527 |
| Aripiprazole | 133 | $12,265 |
| Paliperidone ErPaliperidone | 56 | $8,097 |
| Clozapine | 102 | $6,575 |
| Divalproex Sodium ErDivalproex Sodium | 81 | $5,085 |
| Haloperidol Decanoate | 68 | $4,204 |
| Fluphenazine Decanoate | 37 | $3,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $427 | $388,660186 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $106 | $146,23818 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $507 | $121,35748 claims |
| AbbVieVraylar | $1,510 | $99,06770 claims |
| Alkermes, Inc.Aristada | $1,246 | $81,06124 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,166 | $38,41035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- David HuffmanColumbus$50K
- Tarsicio GacheruColumbus$18K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.